Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.

Clinical cancer research : an official journal of the American Association for Cancer Research - 1 Mar 2000

Middlemas D S, Stewart C F, Kirstein M N, Poquette C, Friedman H S, Houghton P J, Brent T P

Abstract excerpt

The antitumor activity of the methylating agent temozolomide has been evaluated against a panel of 17 xenografts derived from pediatric solid tumors. Temozolomide was administered p.o. daily for five consecutive days at a dose level of 66 mg/kg. Courses of treatment were repeated every 21 days for three cycles. Tumor lines were classified as having high, intermediate, or low sensitivity, determined by complete...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antineoplastic Agents, Alkylating
Share to Dacarbazine

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Mice, Inbred CBA

Share to Neoplasms, Experimental

Share to O(6)-Methylguanine-DNA Methyltransferase

Share to Rhabdomyosarcoma

Share to Temozolomide

Share to Transplantation, Heterologous

Source

Identifiers

PMID: 10741727

Genes

MGMT

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 8 closest

Biochemical correlates of temozolomide sensitivity in pediatric solid tumor xenograft models.PMID 10741727Read ↗

O6-Methylguanine-DNA Methyltransferase, O6-Benzylguanine, and Resistance to Clinical Alkylators in Pediatric Primary Brain Tumor Cell LinesSemantic proximity Read ↗

O6-Methylguanine-DNA methyltransferase in pediatric primary brain tumors: relation to patient and tumor characteristics.Semantic proximity Read ↗

Efficacy of protracted temozolomide dosing is limited in MGMT unmethylated GBM xenograft modelsSemantic proximity Read ↗

Mismatch repair deficiency: a temozolomide resistance factor in medulloblastoma cell lines that is uncommon in primary medulloblastoma tumoursSemantic proximity Read ↗

Phase I trial of temozolomide and protracted irinotecan in pediatric patients with refractory solid tumors.Semantic proximity Read ↗

Effect of aberrant p53 function on temozolomide sensitivity of glioma cell lines and brain tumor initiating cells from glioblastoma.Semantic proximity Read ↗

Antitumor activity of temozolomide combined with irinotecan is partly independent of O6-methylguanine-DNA methyltransferase and mismatch repair phenotypes in xenograft models.Semantic proximity Read ↗

In vivo Evaluation of Ixabepilone (BMS247550), A Novel Epothilone B Derivative, against Pediatric Cancer ModelsSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.